There are currently 2875 clinical trials in Houston, Texas looking for participants to engage in research studies. Trials are conducted at various facilities, including M D Anderson Cancer Center, University of Texas MD Anderson Cancer Center, Baylor College of Medicine and The University of Texas - MD Anderson Cancer Center. Whether you're a healthy volunteer looking to participate in paid medical research or seeking trials related to a specific condition, the city provides a diverse range of opportunities near you.
Evaluate the Neurological Effects of EryDex on Subjects With A-T
NCT06193200
Recruiting
This is an international, multi-center, randomized, prospective, double-blind, placebo-controlled, Phase 3 study, designed to assess the effect of EryDex (dexamethasone sodium phosphate \[DSP\] in autologous erythrocytes), administered by intravenous (IV) infusion once every 28 days, on neurological symptoms of patients with Ataxia Telangiectasia (A-T).
Gender:
ALL
Ages:
6 years and above
Trial Updated:
06/27/2025
Locations: UT Health Houston, Department of pediatrics, division of child & adolescent neurology, Houston, Texas
Conditions: Ataxia Telangiectasia
Register for Updates
AB-2100, an Integrated Circuit T Cell Therapy in Patients With Recurrent Clear-cell Renal Cell Carcinoma (ccRCC)
NCT06245915
Recruiting
This is a multi-center, open-label phase 1/2 trial evaluating the safety and efficacy of AB-2100 cell product. The study may enroll approximately 60 patients in phase 1 and approximately 70 patients in phase 2.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/27/2025
Locations: MD Anderson Cancer Center, Houston, Texas
Conditions: Advanced/Metastatic Clear Cell Renal Cell Carcinoma, Recurrence
Register for Updates
A Safety and Efficacy Study Evaluating CTX131 in Adult Subjects With Relapsed/Refractory Hematologic Malignancies
NCT06492304
Recruiting
This is an open label, multicenter, phase 1/2 dose evaluation and cohort expansion study evaluating the safety and efficacy of CTX131 in subjects with Relapsed/Refractory Hematologic Malignancies
Gender:
ALL
Ages:
Between 18 years and 100 years
Trial Updated:
06/27/2025
Locations: Research Site 1, Houston, Texas
Conditions: T Cell Lymphoma, B Cell Lymphoma, Acute Myeloid Leukemia
Register for Updates
Study of AZD0754 in Participants With Metastatic Prostate Cancer
NCT06267729
Recruiting
The purpose of this study is to evaluate the safety, tolerability, and antitumour activity of AZD0754 CAR T-cell therapy in participants with metastatic prostate cancer.
Gender:
MALE
Ages:
Between 18 years and 130 years
Trial Updated:
06/27/2025
Locations: Research Site, Houston, Texas
Conditions: Metastatic Prostate Cancer
Register for Updates
A Study of Rapcabtagene Autoleucel in Systemic Lupus Erythematosus (SLE) Patients With Active, Refractory Lupus Nephritis (LN)
NCT06581198
Recruiting
The purpose of this study is to evaluate the efficacy and safety of rapcabtagene autoleucel (administered once following lymphodepletion) versus Standard of Care (SOC) in patients with systemic lupus erythematosus (SLE) with active, refractory lupus nephritis (LN).
Gender:
ALL
Ages:
Between 18 years and 65 years
Trial Updated:
06/27/2025
Locations: University of Texas MD Anderson Cancer Center, Houston, Texas
Conditions: Lupus Erythematosus, Systemic, Lupus Nephritis
Register for Updates
Study to Evaluate the Efficacy and Safety of TRL1068 for the Treatment of Prosthetic Joint Infection
NCT06621251
Recruiting
TRL1068 is expected to eliminate the pathogen-protecting biofilm in the prosthetic joint and surrounding tissue, thus making pathogens substantially more susceptible to established antibiotic treatment regimens. This Phase 2 study is designed to assess efficacy and safety of TRL1068 in combination with a DAIR (debridement, antibiotics, and implant retention) procedure for chronic prosthetic joint infections of the knee and hip, specifically, eliminating the need for the standard of care 2-stage... Read More
Gender:
ALL
Ages:
Between 18 years and 85 years
Trial Updated:
06/27/2025
Locations: Houston Methodist, Houston, Texas +1 locations
Conditions: Prosthetic Joint Infections of Hip, Prosthetic Joint Infections of Knee
Register for Updates
Phase III, Open-label, Study of First-line Dato-DXd in Combination With Rilvegostomig for Advanced Non-squamous NSCLC With High PD-L1 Expression (TC ≥ 50%) and Without Actionable Genomic Alterations
NCT06357533
Recruiting
The purpose of this study is to evaluate efficacy and safety of Dato-DXd in combination with rilvegostomig or rilvegostomig monotherapy compared with pembrolizumab monotherapy as a first line therapy in participants with locally advanced or metastatic non-squamous NSCLC with high PD-L1 expression (TC ≥ 50%) and without actionable genomic alterations.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/27/2025
Locations: Research Site, Houston, Texas +2 locations
Conditions: Non-Small Cell Lung Cancer
Register for Updates
A Study to Assess Efficacy, Safety, Tolerability, Pharmacokinetics (PK) and Pharmacodynamics (PD) of RO7204239 in Combination With Tirzepatide in Participants With Obesity or Overweight With At Least One Weight-related Comorbidity
NCT06965413
Recruiting
The main aim of the study is to assess the effect of RO7204239 in combination with tirzepatide, compared to placebo in combination with tirzepatide, on body weight loss after 48 weeks of treatment in adults with obesity or overweight with at least one weight-related comorbidity, but without diabetes mellitus (DM). The study comprises of a 4-week screening period; a 48-week core treatment period, where all participants will receive tirzepatide as background treatment and will be randomized to one... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/27/2025
Locations: Juno Research, LLC, Houston, Texas
Conditions: Obesity, Overweight, Overweight With One Weight Related Comorbidity
Register for Updates
A Phase 2 Study of YA-101 in Patients With Multiple System Atrophy
NCT06848231
Recruiting
This is a Phase 2, double-blind, placebo-controlled, multi-center, Phase II, dose escalation study to evaluate the safety, tolerability, pharmacokinetics and efficacy of Ya-101 in subjects with multiple system atrophy.
Gender:
ALL
Ages:
30 years and above
Trial Updated:
06/27/2025
Locations: Baylor College of Medicine, Houston, Texas
Conditions: Multiple System Atrophy
Register for Updates
Open-label, Long-term Safety Study of Secukinumab in Polymyalgia Rheumatica (PMR)
NCT06331312
Recruiting
The purpose of this extension study is to assess the safety and tolerability of secukinumab when administered long-term in patients with polymyalgia rheumatica.
Gender:
ALL
Ages:
Between 50 years and 100 years
Trial Updated:
06/27/2025
Locations: Prolato Clinical Research Center, Houston, Texas
Conditions: Polymyalgia Rheumatica
Register for Updates
A Phase 2 Trial of Mosunetuzumab and Zanubrutinib for Patients With Relapsed/Refractory Marginal Zone Lymphoma
NCT06563505
Recruiting
To assess the efficacy and safety of mosunetuzumab combined with zanubrutinib in patients with relapsed or refractory MZL.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/27/2025
Locations: MD Anderson Cancer Center, Houston, Texas
Conditions: Lymphoma
Register for Updates
CER-1236 in Patients With Acute Myeloid Leukemia (AML)
NCT06834282
Recruiting
This is a first in human, multi center, open label, phase 1/1b study to evaluate the safety and preliminary efficacy of CER-1236 in patients with relapsed/refractory (R/R), measurable residual disease (MRD) positive acute myeloid leukemia (AML), or TP53mut disease.
Gender:
ALL
Ages:
Between 18 years and 85 years
Trial Updated:
06/27/2025
Locations: The University of Texas MD Anderson Cancer Center, Houston, Texas
Conditions: AML, Acute Myeloid Leukemia, Refractory Acute Myeloid Leukemia
Register for Updates